Enovis (ENOV) came out with quarterly earnings of $0.95 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.98 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +17.28%. A quarter ago, it was expected that this manufacturing and engineering company would post earnings of $0.67 per share when it actually produced earnings of $0.75, delivering a surprise of +11.94%.Over the last four ...

Privia Health (PRVA) came out with quarterly earnings of $0.07 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +67.87%. A quarter ago, it was expected that this physician practice management company would post earnings of $0.06 per share when it actually produced earnings of $0.05, delivering a surprise of -16.67%.Over the la ...

分组1 - Evolent Health reported quarterly earnings of $0.08 per share, exceeding the Zacks Consensus Estimate of $0.06 per share, compared to a loss of $0.02 per share a year ago, representing an earnings surprise of +28.00% [1] - The company posted revenues of $468.72 million for the quarter ended December 2025, missing the Zacks Consensus Estimate by 0.11%, and this is a decline from year-ago revenues of $646.54 million [2] - Evolent Health shares have declined approximately 30.8% since the beginning of the year, while the S&P 500 has only declined by 0.1% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.08 on revenues of $544.44 million, and for the current fiscal year, it is $0.39 on revenues of $2.39 billion [7] - The Zacks Industry Rank indicates that the Medical Info Systems sector is currently in the bottom 40% of over 250 Zacks industries, suggesting potential underperformance compared to higher-ranked industries [8]

分组1 - Hims & Hers Health, Inc. reported quarterly earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, but down from $0.11 per share a year ago, resulting in an earnings surprise of +227.10% [1] - The company posted revenues of $617.82 million for the quarter ended December 2025, which was 0.22% below the Zacks Consensus Estimate, compared to $481.14 million in the same quarter last year [2] - Hims & Hers Health shares have declined approximately 51.9% year-to-date, contrasting with the S&P 500's gain of 0.9% [3] 分组2 - The current consensus EPS estimate for the upcoming quarter is $0.13 on revenues of $645.27 million, and for the current fiscal year, it is $0.55 on revenues of $2.73 billion [7] - The Medical Info Systems industry, to which Hims & Hers Health belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential underperformance compared to higher-ranked industries [8]

分组1 - Claritev Corporation reported a quarterly loss of $4.88 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.96, representing an earnings surprise of -23.23% [1] - The company posted revenues of $246.55 million for the quarter ended December 2025, exceeding the Zacks Consensus Estimate by 2.13%, and showing an increase from $232.15 million year-over-year [2] - Claritev Corporation has surpassed consensus revenue estimates four times over the last four quarters, but has only exceeded consensus EPS estimates once during the same period [2] 分组2 - The stock has underperformed significantly, losing about 45.6% since the beginning of the year, while the S&P 500 has gained 0.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$3.75 on revenues of $243.21 million, and for the current fiscal year, it is -$14.26 on revenues of $992.62 million [7] - The Medical Info Systems industry, to which Claritev Corporation belongs, is currently ranked in the bottom 45% of over 250 Zacks industries, indicating potential challenges for stock performance [8]

iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +1,484.70%. A quarter ago, it was expected that this company would post a loss of $0.36 per share when it actually produced a loss of $0.06, delivering a surprise of +83.33%.Over the last four quarters, the ...

Key Takeaways Hims & Hers is set to post Q4 2025 results, with revenue projected to rise 28.7% year over year.Hims & Hers expanded into low testosterone, menopause care and Labs, boosting subscriber growth.HIMS faces higher marketing and operating costs plus compounded semaglutide legal scrutiny from Novo Nordisk.Hims & Hers Health, Inc. (HIMS) is scheduled to report fourth-quarter 2025 results on Feb. 23, after the closing bell.In the last reported quarter, the company’s earnings per share (EPS) of 6 cents ...

Talkspace, Inc. (TALK) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +50.00%. A quarter ago, it was expected that this company would post earnings of $0.02 per share when it actually produced earnings of $0.02, delivering no surprise.Over the last four quarters, the company has surp ...

Core Insights - Tempus AI, Inc. (TEM) is set to report its fourth-quarter 2025 results on February 24, with expectations of an 82.8% year-over-year revenue increase to $366.8 million [2][7] - The company reported an adjusted loss of 11 cents per share in the last quarter, which was better than the Zacks Consensus Estimate of a loss of 16 cents [1] - Tempus has seen a share price decline of 32.9% in the fourth quarter due to macroeconomic challenges, despite strong momentum from strategic acquisitions and product launches [3][7] Financial Performance - The Zacks Consensus Estimate for loss per share has remained unchanged at 2 cents over the past 30 days [2] - The company's earnings estimate revision trend shows consistent expectations for the current quarter and the next, with losses projected at -0.02 for Q4 and -0.13 for Q1 2026 [3] - In the previous quarter, Tempus achieved a gross profit improvement of 98.4% year-over-year, and adjusted EBITDA turned positive, indicating progress towards profitability [14] Market Position and Competitive Landscape - Tempus trades at a forward price-to-sales (P/S) ratio of 5.82X, which is above the industry average of 5.66X and higher than competitors like 10x Genomics (3.83X) and SOPHiA GENETICS (3.69X) [16] - The Zacks Medical Info Systems industry experienced a loss of 21.6% during the same period, while the S&P 500 gained 3.3% [4] Strategic Developments - Recent collaborations include a multi-year partnership with Whitehawk Therapeutics for oncology treatments and a selection by the Advanced Research Projects Agency for Health to provide testing services [8] - The Genomics segment is expected to show improvement due to growth in oncology testing and hereditary sequencing, while the Data and Services business is likely to benefit from strong demand for proprietary data licensing and AI solutions [9][10] - Tempus has enhanced its capabilities through the acquisition of Paige, an AI leader in digital pathology, and expanded its collaboration with Northwestern Medicine to integrate AI into clinical workflows [12] Future Outlook - The AI market is anticipated to grow rapidly, positioning Tempus to capitalize on emerging opportunities in healthcare [17] - Despite recent upsides, the company's premium valuation and lack of near-term profitability may limit immediate gains [18]

Core Insights - Tempus AI (TEM) is set to release its fourth-quarter 2025 results on February 24, 2026, after market close, with expectations of strengthened performance in 2026 due to strategic collaborations and product innovations [1] Financial Performance - Preliminary results indicate that revenues for the full year 2025 reached approximately $1.27 billion, marking an 83% year-over-year increase, with about 30% of this growth being organic [2] - Diagnostics revenues totaled around $955 million, reflecting a 111% year-over-year increase, driven by a 26% growth in oncology volume and a 29% increase in hereditary testing volume [3] - Data and applications revenues reached approximately $316 million, showing a 31% year-over-year growth, partly due to a 38% improvement in the Insights (data licensing) business [3][4] - The company achieved a Total Contract Value (TCV) of over $1.1 billion as of December 31, 2025, and reported positive adjusted EBITDA of $1.5 million in Q3 2025, a year-over-year improvement of $23.3 million [12] Strategic Collaborations - Tempus has entered a multi-year collaboration with Whitehawk Therapeutics, leveraging its proprietary dataset to enhance oncology research and clinical trial design [7][8] - The company initiated a research study with the Institute for Follicular Lymphoma Innovation, marking its first collaboration with a nonprofit to create a robust dataset for follicular lymphoma [11] Market Position and Challenges - Despite significant revenue growth, Tempus' stock price has declined by 32.9% in Q4, reflecting a broader negative sentiment in the AI medtech sector [6] - The stock currently trades at a price-to-book (P/B) ratio of 17.79X, which is above the industry average of 8.76X, raising valuation concerns [10][20] - The company continues to face challenges with GAAP losses due to stock-based compensation and amortization of acquired intangibles, limiting visibility into sustainable profitability [17][18] Future Outlook - The company is positioned as a high-growth leader at the intersection of AI and precision medicine, with strong operational momentum expected to continue into 2026 [21] - Investors are advised to maintain their positions in Tempus stock, which is currently rated as a Zacks Rank 4 (Sell) [22]